Evidence map›Paper›PMID 35638450›Full record

ReviewBioscience reports2022

Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Kasturee Chakraborty, Archana Tripathi, Sukumar Mishra, Argha Mario Mallick, Rituparna Sinha Roy

Abstract readReview
In one paragraph

Review in Bioscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Chemotherapeutic Activity of Imidazolium-Supported Pd(II)Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kasturee Chakraborty *Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India.
Archana Tripathi *Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India.
Sukumar Mishra *Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India.
Argha Mario Mallick *Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India.
Rituparna Sinha RoyDepartment of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India.ORCID 0000-0003-3450-1017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotherapy has emerged as an improved anticancer therapeutic strategy to circumvent the harmful side effects of chemotherapy. It has been proven to be beneficial to offer multiple advantages, including their capacity to carry different therapeutic agents, longer circulation time and increased therapeutic index with reduced toxicity. Over time, nanotherapy evolved in terms of their designing strategies like geometry, size, composition or chemistry to circumvent the biological barriers. Multifunctional nanoscale materials are widely used as molecular transporter for delivering therapeutics and imaging agents. Nanomedicine involving multi-component chemotherapeutic drug-based combination therapy has been found to be an improved promising approach to increase the efficacy of cancer treatment. Next-generation nanomedicine has also utilized and combined immunotherapy to increase its therapeutic efficacy. It helps in targeting tumor immune response sparing the healthy systemic immune function. In this review, we have summarized the progress of nanotechnology in terms of nanoparticle designing and targeting cancer. We have also discussed its further applications in combination therapy and cancer immunotherapy. Integrating patient-specific proteomics and biomarker based information and harnessing clinically safe nanotechnology, the development of precision nanomedicine could revolutionize the effective cancer therapy.

Indexed as

NanoparticlesNeoplasmsHumansImmunotherapyNanomedicineNanotechnologyCancerCombination therapyImmuno therapyNanomedicinepeptide

Identifiers

PMID35638450
PMCPMC9272595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.